| Diplôme |
Université |
Pays |
Année |
| Hematology-Oncology Fellowship |
University of Texas Southwestern Medical Center |
Etats-Unis |
2012 |
| American Board of Medical Oncology |
ABIM/ABMS (American Board of Medical Specialties) |
Etats-Unis |
2012 |
| American Board of Hematology |
ABIM/ABMS (American Board of Medical Specialties) |
Etats-Unis |
2012 |
| Internal Medicine Chief Residency |
SUNY Upstate Medical University |
Etats-Unis |
2009 |
| American Board of Internal Medicine |
ABIM (American Board of Internal Medicine) |
Etats-Unis |
2008 |
| Internal Medicine Residency |
SUNY Upstate Medical University |
Etats-Unis |
2008 |
| MD |
Saint Joseph University of Beyrouth |
Liban |
2004 |
| Enseignement universitaire hors USJ |
Pays |
Etablissement |
Date début |
Date fin |
| Internal Medicine & Hematology-Oncology Clinical Instructor, University of Utah, Huntsman Cancer Institute |
Etats-Unis |
University of Utah, Huntsman Cancer Institute |
01/03/2015 |
30/06/2018 |
| Internal Medicine Chief Resident, SUNY Upstate Medical University Hospital |
Etats-Unis |
SUNY Upstate Medical University Hospital |
01/07/2008 |
30/06/2009 |
| Expérience professionnelle |
Organisation |
Date début |
Date fin |
| Hematologist-Oncologist, Northern Light Health-Eastern Maine Medical Center, Bangor, ME, USA |
Northern Light Health-Eastern Maine Medical Center, Bangor, ME |
01/01/2022 |
30/09/2024 |
| Hematologist-Oncologist, St Michael Hospital Cancer Center, Texarkana, TX, USA |
St Michael Hospital Cancer Center, Texarkana, TX, USA |
07/01/2021 |
30/06/2022 |
| Hematologist-Oncologist, Hotel-Dieu de France University Hospital |
Hotel-Dieu de France University Hospital |
01/04/2018 |
11/11/2024 |
| Hematologist-Oncologist, Clemenceau Medical Center |
Clemenceau Medical Center |
01/10/2017 |
11/11/2024 |
| Medical Director, Hematologist-Oncologist, Sweetwater Regional Cancer Center, an Affiliate of Huntsman Cancer Institute, University of Utah, NCI-Designated Comprehensive Cancer Center |
Sweetwater Regional Cancer Center, an Affiliate of Huntsman Cancer Institute, University of Utah, NCI-Designated Comprehensive Cancer Center |
01/08/2012 |
30/09/2017 |
Médecine et Santé
Targeted Therapies Immunotherapy: Neuro, ENT, Breast, Gynecological, Pulmonary, Digestive, Urinary, Sarcomas, Dermatology, Benign Malignant Hematology
Genetic markers of chronic lymphocytic leukemia: a retrospective study of 312 patients from a reference center in Lebanon. Future Oncology 2023 Sep19(29):1991-2002.Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey. Future Oncology 2021 Nov 17(31):4071-4079.Helou S., Helou E., Abou-Khalil V., Wakim J., et al. The effect of the COVID-19 pandemic on physicians’ use perception of telehealth: The case of Lebanon. Int. J. Environ. Res. Public Health 2020, 17, 4866Chaudary P., Wakim J., Khadim H., Karumbaiah KK., Gajra A. Acquired factor X deficiency in systemic amyloidosis: management of two cases. Haemophilia, 2013 Nov 19(6): e375-6.Wakim JJ., Levenson BM., Matthews D., Naina H. Management of an unusual case of intravascular large B-cell lymphoma of the penis, prostate, bones with CNS relapse. Journal of Clinical Oncology, 2013 June 1031(17):e288-9.Wakim JJ., Tirado CA., Dowell J., and Chen W. The first case of Philadelphia-negative acute promyelocytic leukemia following imatinib for chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 2012 March;205(3): p124-127.Wakim JJ. and Tirado CA (January 2012). Acute promyelocytic leukemia lacking the classic translocation t(15;17). In: Koschmieder, S. and Krug, U. (Editors). Myeloid Leukemia – Clinical Diagnosis and Treatment. Chapter 12, p219-234. Intech.Wakim JJ., Tirado CA., Chen W., and Collins R. t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leukemia Research, 2011Sep;35(9):e151-3
https://01-397082/71-780238/71-911411